Previous EGFR IHC studies of cervical carcinomas show a wide range of expression levels (6–100%) [16, 18]; these data may be a reflection of differences in antibody clone choices, IHC protocols, and/or in how staining was rated [16]. This evidence concerns the gene EGFR and cervical carcinoma.